Zymeworks Presents Safety And Anti-Tumor Activity Data From The Ongoing Phase I Study Of ZW25 At ASCO Annual Meeting (ASCO 2017) Post author:Sam Post published:June 4, 2017 Post category:BioPharma Life Sciences Jobs … Source: BioSpace You Might Also Like Axovant's Much-Hyped Alzheimer's Drug Flunks Phase III Test September 25, 2017 Reata Pharmaceuticals, Inc. Announces First Quarter 2017 Financial And Operating Results May 10, 2017 PharmaMar Announces New Data With Its Compounds Yondelis And Lurbinectedin During ASCO 2017 May 18, 2017
Reata Pharmaceuticals, Inc. Announces First Quarter 2017 Financial And Operating Results May 10, 2017
PharmaMar Announces New Data With Its Compounds Yondelis And Lurbinectedin During ASCO 2017 May 18, 2017